EDVIPNCT06431945
Early Detection of HCV in Injection Drug Users
StatusCompleted
PhaseNot specified
Primary completion
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 3 words Show 4 more changesShow less
- Trial completed
- Enrollment target: estimated 3000 to confirmed 2776
- Study description revised
- Site details revised at 18 of 18 sites
- Notable Primary completion date: May 31, 2025 to Dec 31, 2025v2
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Incidence of the hepatitis C virus in screened cohort of persons who inject drugs
Timeframe: Until 31. 12. 2025
Secondary (2)
Up to 3,000 persons who inject drugs (PWID) enrolled in the project
Optimal methodological settings for early detection of the Hepatitis C virus based on hepatitis C antibody and hepatitis C RNA testing
Arms and interventions
People who inject drugs
Diagnostic tests: Hepatitis C antibody (anti-HCV) test, Hepatitis C RNA test and genotype test
Sites
18 sites in 1 country